Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.
Past Team (4)Update
Funding Rounds (2) - $32.5MUpdate
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing...
Novo A/S is the holding company of the Novo Group, wholly-owned by the Novo Nordisk Foundation.
IT and Healthcare VC
Premier angel investment group
400 Oyster Point Boulevard
South San Francisco, CA 94080